Table 1.
Age at treatment initiation and short-term GH treatment outcomes in children born SGA
| Study | N | Design/Duration | Agea/Model | Outcome (∆HSDS or statistical model) | PValue |
|---|---|---|---|---|---|
| Argente 2007 [46] |
39b |
MC, C, R, O/2 years |
2 to <4 years |
1.7 at 1 year; approximately 2.5 at 2 years |
<0.05 |
| |
|
|
4 to 5 years |
1.2 at 1 year; approximately 1.8 at 2 years |
|
| Carvalho-Furtado 2009 [47] |
39 |
Ob/1 year |
Prepubertal |
0.75 |
=0.016 |
| |
|
|
Pubertal |
0.40 |
|
| Lee 2008 [16] |
433 |
MC, NordiNet IOS/≥1 year |
Mean age 6.7 to 9.3 |
6.7 years = 1.0 and 0.8; 7.6 years = 0.72; 8.3 years = 0.61; 9.3 years = 0.57 |
<0.0001c |
| Ranke 2003 [19] |
613 year 1; |
KIGS, clinical trials/2 years |
Mean age 6.6/statistical models predicting growth response |
Year 1: GH dose (35% of variability), age at treatment start (11% of variability) |
<0.0001 <0.0001 |
| |
385 year 2 |
|
|
Year 2: HV in year 1 of treatment (29% of variability), age at treatment start (3% of variability), GH dose (2% of variability) |
|
| Ross 2010 [15] | 208 year 1;119 year 2 | ANSWER Program registry/2 years | Mean age 8.4/males <11 years vs ≥11 years; females <10 years vs ≥10 years | Year 1 boys: <11 years = 0.82; ≥11 years = 0.27Year 1 girls: <10 years = 0.58; ≥10 years = 0.41Year 2 boys: <11 years = 1.23; ≥11 years = 0.59Year 2 girls: <10 years = 1.00; ≥10 years = 0.87 | <0.0001 = 0.093 = 0.0005 = 0.56 |
aAge at treatment initiation; bData are reported for study group 1 with 2 years GH treatment; cMultivariate analysis showed ∆HSDS was dependent on age at the start of treatment. ANSWER, American Norditropin Studies: Web-enabled Research; C, controlled; GH, growth hormone; ∆HSDS, change in height SDS; HV, height velocity; IOS, international outcome study; KIGS, Pharmacia International Growth Database; MC, multicenter; O, open trial; Ob, observational; R, randomized; SDS, standard deviation score.